<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194960</url>
  </required_header>
  <id_info>
    <org_study_id>TV2/001/09</org_study_id>
    <nct_id>NCT01194960</nct_id>
  </id_info>
  <brief_title>TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)</brief_title>
  <official_title>A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford BioMedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedSource LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxford BioMedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer&#xD;
      vaccine before chemotherapy to enhance immune responses, thus leading to a more effective&#xD;
      therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the&#xD;
      role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression&#xD;
      free survival (PFS) of subjects with HRPC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Week 37</time_frame>
    <description>To establish whether the incidence of progression-free survival (as defined by the absence of progression assessed by both RECIST and PCWG2 criteria) at week 37 in the TroVax® plus Docetaxel treatment arm is higher than the incidence in the Docetaxel alone treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical progression-free survival</measure>
    <time_frame>37 weeks</time_frame>
    <description>To establish whether the incidence of clinical progression-free survival (defined by the absence of progression assessed by RECIST criteria alone) at week 37 in the TroVax® plus Docetaxel treatment arm is higher than the incidence in the Docetaxel alone treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hormone Refractory Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TroVax plus Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive both TroVax plus 10 cycles of Docetaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.</description>
    <arm_group_label>Docetaxel Alone</arm_group_label>
    <arm_group_label>TroVax plus Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TroVax</intervention_name>
    <description>Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37</description>
    <arm_group_label>TroVax plus Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Signed &amp; dated written informed consent obtained from subject in accordance w/local&#xD;
             regulations.&#xD;
&#xD;
          2. Histologically confirmed conventional and/or mucinous adenocarcinoma of the prostate.&#xD;
             If histological confirmation is not available, cytological confirmation will be&#xD;
             permitted in lieu.&#xD;
&#xD;
          3. Must meet one of following 3 criteria for progressive disease following androgen&#xD;
             deprivation:&#xD;
&#xD;
        A. Subjects w/nodal or visceral metastases:&#xD;
&#xD;
        Must have progressive disease defined by RECIST criteria or defined by the Prostate Cancer&#xD;
        Clinical Trials Working Group II (Scher et al. 2008).&#xD;
&#xD;
        B. Subjects w/no measurable disease:&#xD;
&#xD;
        PSA only disease must have an elevated PSA as defined by Consensus Criteria Prostate Cancer&#xD;
        Clinical Trials Working Group II (Scher et al. 2008). PSA must indicate progressive disease&#xD;
        defined as rising PSA values, at least 7 days apart, &gt;2 ng/mL in the 28 days prior to&#xD;
        randomization.&#xD;
&#xD;
        C. Subjects w/bone involvement:&#xD;
&#xD;
        New disease on bone scan as defined by Consensus Criteria Prostate Cancer Clinical Trials&#xD;
        Working Group II (Scher et al. 2008). 4. Subjects on stable dose of bisphosphonates showing&#xD;
        subsequent tumor progression may continue on this medication; however, subjects are not&#xD;
        allowed to initiate bisphosphonate therapy w/in 28 days prior to starting study treatment&#xD;
        at Week 1 or at any time after that during the study, 5. Must be clinically&#xD;
        immunocompetent. Clinical immunocompetence assumed unless subject has been diagnosed as&#xD;
        immunosuppressed, is receiving immunosuppressive chemotherapy for oncology disorders, or is&#xD;
        receiving immunosuppressive therapy following transplant, in which case they will be&#xD;
        excluded.&#xD;
&#xD;
        6. Subject free of clinically apparent/active autoimmune disease (no prior confirmed&#xD;
        diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis,&#xD;
        Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, &amp; Rheumatoid Arthritis).&#xD;
&#xD;
        7. Subject has adequate bone marrow function defined by Absolute Lymphocyte Count (ALC) ≥&#xD;
        500/µL, Absolute Neutrophil Count (ANC) &gt;1200/µL, Platelet Count &gt;100,000/µL.&#xD;
&#xD;
        8. Subject has peripheral neuropathy grade ≤1. 9. Subject has ECOG status of 0 or 1. 10.&#xD;
        Minimum life expectancy ≥6 months. 11. Progressive disease (as defined above) must be&#xD;
        documented after discontinuation of the hormonal and anti-androgen therapy.&#xD;
&#xD;
        12. Subject continues to stay on medical treatment such as LHRH agonists or LHRH&#xD;
        antagonists to maintain testosterone value of &lt;50ng/dL.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Subject has received prior chemotherapy for prostate cancer at any time. Subject has&#xD;
             received chemotherapy for any other reason within five years of screening.&#xD;
&#xD;
          2. Subject is receiving any other hormonal therapy, including any dose of Megestrol&#xD;
             Acetate, Finasteride, any herbal product known to decrease PSA levels (e.g., Saw&#xD;
             Palmetto &amp; PC-SPES), or any systemic corticosteroid must discontinue agent for at&#xD;
             least 4 weeks prior to the anticipated Week 1 visit. LHRH agonists or LHRH antagonists&#xD;
             do not need to be discontinued.&#xD;
&#xD;
          3. Subject has started bisphosphonate or denosumab therapy less than 28 days before the&#xD;
             anticipated Week 1 visit.&#xD;
&#xD;
          4. Subject is using supplements or complementary medicines/botanicals. Subjects should&#xD;
             review label w/their doctor prior to enrolment. Exceptions to this exclusion:&#xD;
&#xD;
               -  Conventional multivitamin supplements&#xD;
&#xD;
               -  Selenium&#xD;
&#xD;
               -  Lycopene&#xD;
&#xD;
               -  Soy supplements&#xD;
&#xD;
               -  Vitamin E&#xD;
&#xD;
               -  Fish oil supplements&#xD;
&#xD;
               -  Vitamin D&#xD;
&#xD;
               -  Glucosamine supplements&#xD;
&#xD;
               -  Age-related eye disease vitamins&#xD;
&#xD;
               -  Ginkgo biloba&#xD;
&#xD;
          5. Subject has had major surgery or radiation therapy completed &lt;4 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          6. Corticosteroids are not permitted except for (a) nasal sprays and inhalers, (b) orally&#xD;
             prescribed as replacement therapy in the case of adrenal insufficiency, (c) oral or IV&#xD;
             dexamethasone administration used acutely in combination with docetaxel, (d)&#xD;
             parenteral use on a single occasion, (e) low dose parenteral use for a maximum of 5&#xD;
             days and (f) acute and sporadic parenteral use for acute asthma.&#xD;
&#xD;
          7. Subject is known to test positive for HIV or hepatitis B or C.&#xD;
&#xD;
          8. Subject receiving concurrent chemotherapy, immunotherapy, radiotherapy or&#xD;
             investigational agents.&#xD;
&#xD;
          9. Subject has Platelet count &gt;400,000/μL; Monocytes &gt;80,000/μL; Haemoglobin &lt;11g/dL.&#xD;
&#xD;
         10. Subject has cerebral metastases (known from previous investigations or clinically&#xD;
             detectable).&#xD;
&#xD;
         11. Subject has serum testosterone &gt;50ng/dL.&#xD;
&#xD;
         12. Subject has rheumatoid disease (asymptomatic subjects w/controlled &amp; rarely flaring&#xD;
             rheumatoid arthritis are also excluded).&#xD;
&#xD;
         13. Subject exhibits evidence of symptomatic congestive heart failure, pulmonary embolus,&#xD;
             vascular thrombosis, transient ischemic attack, cerebrovascular accident, unstable&#xD;
             angina, myocardial infarction or active ischemia on ECG. If an ECG taken prior to&#xD;
             screening but within 28 days of the anticipated Week 1 visit is not available, an ECG&#xD;
             must be performed at screening.&#xD;
&#xD;
         14. Subject has uncontrolled severe hypertension &gt;150/100mm Hg (if controlled w/medication&#xD;
             this is not an exclusion).&#xD;
&#xD;
         15. Subject is hypotensive.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna C. Ferrari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Bernardino Urology</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Harrop R, Chu F, Gabrail N, Srinivas S, Blount D, Ferrari A. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunol Immunother. 2013 Sep;62(9):1511-20. doi: 10.1007/s00262-013-1457-z. Epub 2013 Jul 23.</citation>
    <PMID>23877659</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <disposition_first_submitted>September 29, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 8, 2020</disposition_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer of prostate</keyword>
  <keyword>cancer of the prostate</keyword>
  <keyword>neoplasms prostate</keyword>
  <keyword>neoplasms prostatic</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>prostate neoplasms</keyword>
  <keyword>prostatic cancer</keyword>
  <keyword>prostate specific antigen</keyword>
  <keyword>prostatic hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

